anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing Cannabis Semen ethanol extract is provided to effectively treat pancreatic cancer. CONSTITUTION: A composition for preventing and treating pancreatic cancer contains Cannabis Semen ethanol extract as an active ingredient, prepared at 50 Deg. C. for 24 hours. The composition also contains pharmaceutically acceptable carrier or diluents. A functional food for preventing pancreatic cancer contains 0.1-5 wt% of the extract as an active ingredient. The functional food is meats, sausages, breads, chocolates, candies, snack, pizza, ramen, other noodles, gum, dairy products, soups, beverage, tea, drink, or vitamin complex. [Reference numerals] (AA) Relative cell survival rate
ABSTRACT OF THE INVENTION    The invention discloses an antimicrobial compo-sition composed of an antimicrobial polypeptide and a hypothiocyanate component.  Synergistic activity is seen when the composition is applied at between about 30 and 40 degrees Centigrade at a pH between about 3 and about 5.  The composition is useful against gram negative bacteria such as Salmonella and E. coli.  A preferred composition is nisin, lactoperoxidase, thiocyanate and hydrogen peroxide.  Such a composition is capable of reducing the viable cell count of Salmonella by greater than 6 logs in 10 to 20 minutes.     MS #1624.1
BACKGROUND: Metastasis is one of the main factors leading to the high mortality rate of gastric cancer. The current monitoring methods are not able to accurately monitor gastric cancer metastasis.
METHODS: In this paper, we constructed a new type of hollow  Mn 3 O 4   nanocomposites,  Mn 3 O 4   @HMSN-Cy7.5-FA, which had a size distribution of approximately 100 nm and showed good stability in different liquid environments. The in vitro magnetic resonance imaging (MRI) results show that the nanocomposite has good response effects to the acidic microenvironment of tumors. The acidic environment can significantly enhance the contrast of T 1  -weighted MRI. The cellular uptake and endocytosis results show that the nanocomposite has good targeting capabilities and exhibits good biosafety, both in vivo and in vitro. In a gastric cancer nude mouse orthotopic metastatic tumor model, with bioluminescence imaging's tumor location information, we realized in vivo MRI/fluorescence imaging (FLI) guided precise monitoring of the gastric cancer orthotopic and metastatic tumors with this nanocomposite.
RESULTS: This report demonstrates that  Mn 3 O 4   @HMSN-Cy7.5-FA nanocomposites is a promising nano-diagnostic platform for the precision diagnosis and therapy of gastric cancer metastasis in the future.
CONCLUSIONS: In vivo MRI/FLI imaging results show that the nanocomposites can achieve accurate monitoring of gastric cancer tumors in situ and metastases. BLI's tumor location information further supports the good accuracy of MRI/FLI dual-modality imaging. The above results show that the MHCF NPs can serve as a good nano-diagnostic platform for precise in vivo monitoring of tumor metastasis. This nanocomposite provides more possibilities for the diagnosis and therapy of gastric cancer metastases.
Surgical resection of the affected portion of the liver offers the best chance for disease-free survival in patients with hepatoma (HCC). Unfortunately, most hepatoma patients present with disease that is not amenable to resection (multifocal disease) or have other medical contraindications to surgery (limited hepatic reserve related to advanced cirrhosis or chronic hepatitis). Fewer than 15%1 of hepatoma patients are suitable surgical candidates.

The objective of treatment with TheraSphere is to selectively administer a potentially lethal dose of radioactive material to neoplastic tissue in the liver of patients with HCC. Regional therapies for HCC may have several advantages over systemically administered treatments. Irradiating a cancer prior to treatment with regional chemotherapy may be more effective than either therapeutic modality alone. TheraSphere may also be of value as a 'bridging' treatment for HCC patients awaiting a donor organ for liver transplantation.
PURPOSE:To obtain the subject accelerator of alcoholic metabolism accelerating metabolism of alcohol digested into a living body and suppressing generation of ketone or keto acid containing omega6-based unsaturated fatty acid. CONSTITUTION:The objective accelerator is obtained by containing omega6-based unsaturated fatty acid (e.g. gamma-linolenic acid) and suitable amounts of other components such as vitamin, mineral, sweetener, coloring matter, bulk filler or shaping agent and subjecting to formulation. Said accelerator is able to be prepared in a shape of powder, tablet, paste, liquid or capsule, etc. Microorganism producible of lipid containing gamma-linolenic acid belonging to genus Mucor is cultured to obtain said gamma-linolenic acid. Said accelerator of alcoholic metabolism is able to avoid a symptom of headache or vomiting and able to maintain normal body conditions.
### Vials (Injection Concentrate)

THIS PREPARATION MUST BE DILUTED BEFORE USE. The intravenous dose should be prepared by aseptically withdrawing the concentrate from the vial of ciprofloxacin injection. This should be diluted with a suitable intravenous solution to a final concentration of 1 - 2 mg/mL. (See COMPATIBILITY AND STABILITY.) The resulting solution should be infused over a period of 60 minutes by direct infusion or through a Y-type intravenous infusion set which may already be in place.

If the Y-type or "piggyback" method of administration is used, it is advisable to discontinue temporarily the administration of any other solutions during the infusion of ciprofloxacin injection. If the concomitant use of ciprofloxacin injection and another drug is necessary each drug should be given separately in accordance with the recommended dosage and route of administration for each drug.
Sustained release oral pharmaceutical compositions comprise a multitude of medicinal pellets randomly coated with a fatty acid coating containing one or more C12 to C22 saturated fatty acids, the coating being modified by an inert dusting powder which forms channels and weak spots in the otherwise continuous coating.  The fatty acid mixture may include up to 15% by weight of C12 to C22 unsaturated fatty acids.  Inert powders may be one or more of talc, kaolin, silica gel, diatomaceous earth, or precipitated chalk. Suitable pellets are inert pellets-e.g. non-pateil seeds-coated with medicament before the fatty acid coating is applied; the latter is applied in a molten state or in solution in a voltatile organic solvent, which is then evaporated, the inert dusting powder applied, and then further alternating coats of fatty acid and powder to give a final thickness that provides a suitable sustained release.  Active agents which may be used include hormones, enzymes, vasoconstritive amines, alkaloids, steroids, analygesics, bronchodilators, antihistamines, antitussives, antibiotics, diuretics, sulphonamides, sympathomimetics, and barbiturates; such as dexamethasone, prednisolone, isoproterenol, codeine, atropine, scopolamine, hyoscyamine, morphine, penicillin, streptomycin, tetracycline, chlortetracycline, cortisone, hydrocortisone, cyproheptadine, chlorthiazides, amphetamine, chloroprophenpyridamine, phenobarbital, barbital, and amobarbital, and amitriptyline.
RNA-binding motif protein 3 (RBM3), as a cold-inducible protein, exhibits neuroprotective function in brain disorders. This study was conducted to investigate the effects of RBM3 on acute brain injury (ABI) and its underlying mechanism. The cerebral injury (CI) rat model and oxygen-glucose deprivation (OGD) cell model were established. The neurological severity score, wire-grip score, morris water maze test, and Y-maze test were used to detect the neurological damage, vestibular motor, learning, and memory functions. Cerebral injury, apoptosis, oxidative stress, and inflammatory level were evaluated by hematoxylin-eosin and TUNEL staining and specific kits. Flow cytometry was used to analyze the apoptosis rate. The relationship between RBM3 and growth arrest specific (GAS) 6 was analyzed by RNA immunoprecipitation assay. The results indicated that RBM3 recovered of neurological function and behaviour impairment of CI rats. Additionally, RBM3 reversed the increased oxidative stress, inflammatory level, and apoptosis induced by CI and OGD. RBM3 interacted with GAS6 to activate the Nrf2 signaling pathway, thus playing neuroprotection on ABI. Besides, the results of RBM3 treatment were similar to those of mild hypothermia treatment. In summary, RBM3 exerted neuroprotection and ameliorated inflammatory levels and oxidative stress by stabilizing GAS6 mRNA through the Nrf2 signaling pathway, suggesting that RBM3 might be a potential therapeutic candidate for treating ABI.
This is a prospective, open-label, single-center, pilot study. The patient population will include 20 patients who are on the kidney transplant waitlist at NYU Langone Health, are hepatitis C virus (HCV) negative, are willing to accept an organ from an HCV positive donor, and consent to participate in this trial. Study subjects will receive a kidney transplant from a deceased donor who tested positive for HCV as confirmed by nucleic acid amplification testing (NAT) per standard of care. All study subjects will receive a two week course of preemptive therapy with glecaprevir/pibrentasvir (Mavyret®), starting on postoperative day (POD) 0 prior to the transplant. If HCV RNA is undetectable after 2 weeks of therapy, Mavyret will be discontinued and study subjects will be followed with an intensive HCV monitoring protocol. If HCV RNA is detectable after 2 weeks of therapy, Mavyret will be continued to complete a full course of 8 weeks per standard of care. All patients will undergo close monitoring and surveillance for HCV viremia post-transplant to ensure that sustained virologic response (SVR) is achieved.
Chronic mechanical low back pain is common among different age groups and genders. Different manual therapy techniques combined with exercise therapy and electrotherapy modalities play an important role in its management. Our objective was to compare the effects of McKenzie extension exercises program versus Mulligan Techniques for chronic unilateral radicular low back pain. The primary objective of my study is to evaluate the outcome of Mulligan technique versus McKenzie extension exercise with manual traction in patients with chronic unilateral radicular low back pain in terms of pain reduction and ROM.

A randomized control trial will be conducted at Rehab Care and Jinnah Hospital Lahore, from 1st June - 31st January 2024. Both genders and age range 28-50 years clinically diagnosed patient with Lumbar radiculopathy will be included. The patients with Fracture, Trauma, Inflammatory disorder, acute disc bulge, Lumbar instability will be excluded. Subjects will be divided into two equal groups through a computer-generated random number. Sixteen patients in group A will be treated with Mulligan techniques and Sixteen patients in group B with McKenzie for four weeks at two session per week and single session per day. Visual Analogue Scale, Oswestry Disability Scale and lumbar Range of Motion will be used as an assessment tool and were measured at baseline and at the completion 4 weeks intervention. The data will be entered and analyzed with SPSS to draw the statistical and clinical significance of both interventions. Results will be presented as mean and standard deviation for numerical variables like Visual Analogue Scale, Oswestry Disability Scale and lumber Range of Motion. Analysis will be done by statistical package for social sciences SPSS 29
The etiology of Guillain-Barré syndrome (GBS) may be autoimmune. About two-thirds of patients typically experience their first symptoms within 5 days to 3 weeks after common infectious diseases, surgery, or vaccination. Infection is a triggering factor for over 50% of patients. In recent years, a growing number of studies have indicated that some immune checkpoint inhibitors and COVID-19 may also contribute to the occurrence of GBS. However, drugs are considered a rare cause of GBS. The patient in our case was a 70-year-old man who developed GBS after initiating secukinumab for psoriasis. Upon diagnosis suggesting a potential association between secukinumab and the development of GBS, as per the Naranjo adverse drug reaction (ADR) probability scale, we decided to discontinue the drug. Following this intervention, along with the administration of immunoglobulin, the patient exhibited a significant improvement in extremity weakness. The association of GBS with secukinumab treatment, as observed in this case, appears to be uncommon. The underlying mechanisms that may link secukinumab to the development of GBS are not yet fully understood and warrant further scientific inquiry and rigorous investigation. However, we hope that this report can raise greater awareness and vigilance among medical professionals to enhance the safety of patients' medication.
This study enrolled 627 subjects with Major Depressive illness at New York State Psychiatric Institute and Massachusetts General Hospital. Subjects were treated with fluoxetine 10-60mg over a 12 week period. The "responder" group was defined by those no longer meeting criteria for Major Depression at week 12, along with CGI ratings of "much improved" or "very much improved" as determined by an independent evaluator. At week 12 "non-responders" were withdrawn from the study and received open label treatment; responders were randomized in double-blind fashion to either fluoxetine continuation (20-80mg daily) at response dose or placebo switch for up to 24 weeks. The responder group was stratified by "specific or true" drug response (late onset and persistent once attained) and "nonspecific or placebo" response (early onset or nonpersistent) patterns. Subjects were evaluated at one week and two week intervals at different phases of continuation treatment, and depression relapse was determined by agreement between study psychiatrist and independent evaluator CGI and Ham-D ratings, as well as administration of the MDD section of the Mood Disorders Module of the Structured Clinical Interview for DSM-IV Disorders at those visits. A subset of study participants also provided DNA samples to determine whether there are any DNA markers of response type. Data were analyzed to test the following hypotheses: that during continuation fluoxetine treatment improved patients with a "true drug" acute response pattern randomized to placebo had a poorer outcome than those maintained on active drug; that during continuation fluoxetine treatment improved patients with a "placebo" acute response pattern randomized to placebo had no worse an outcome than those maintained on drug; that during continuation fluoxetine treatment patients with a "true drug" acute response pattern randomized to continue on fluoxetine were more likely to maintain their benefit than those with a "placebo" pattern.
Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
The invention concerns cosmetic compositions comprising: A) at least one anionic surfactant and at least one nonionic surfactant, and B) at least one ethylene copolymer comprising, in weight percentage based on the total weight of the polymer: a) 10-60 wt. % of one or more monomers of formula (I) as defined below, b) 40-90 wt. % of at least one substantially cationic monomer selected among: (i) one or more cationic monomers of formula (IIa), (ii) one or more amphoteric monomers of formulae (IIc) and (IId), and (iii) a mixture of one or more cationic monomers of formula (IIa) with one or more anionic monomers selected among maleic anhydride and/or those of formula (IIb); and/or with one or more amphoteric monomers selected among those of formulae (IIc) and (IId), and c) optionally 0-50 wt. % of nonionic hydrophilic monomers, excluding methyl acrylate, methyl methacrylate and isopropyl acrylate if they are present in an amount not less than 10 wt. %. Hair treated with said compositions are more easily disentangled during rinsing, and exhibits softness after drying. The inventive compositions also allow particularly interesting hair brushing after drying.
This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
The method involves registering actually executed actions of medical workflows (W1-W3) by terminals (2, 3) e.g. personal digital assistant, of an electronic control device (1) e.g. computer system with a central server, where a set of workstations is connected to the control device over a computer network. Absolute duration of the actions is continuously measured till the execution of the actions is received at a user-side. An alarm-routine i.e. output of an optical or acoustical alarm signal, is excited when the absolute duration of the actions exceeds action-specific limit duration. An independent claim is also included for an electronic control device with a terminal for executing a method for real time-controlling of manual execution of medical workflow.
Naproxen has analgesic, anti-inflammatory, and antipyretic properties.

The mechanism of action of naproxen, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Naproxen is a potent inhibitor of prostaglandin synthesis in vitro. Naproxen concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because naproxen is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
1429184 Anti-inflammatory steroid crystallisates ALLEN & HANBURYS Ltd 18 April 1973 [20 April 1972] 18421/72 Heading C2U [Also in Division C4] The invention comprises an anti-inflammatory steroid in the form of a crystalline solvate with a halobydrocarbon or such a crystalline material from which part or all of the halohydrocarbon has been removed, the particle size of substantially all of the steroid material being such as to permit inhalation into the human bronchial system when dispersed as an aerosol, e.g. 2- 20 Á. Several specific steroids of the pregna-1,4- diene-3,20-dione series are mentioned. Specified halohydrocarbons are CH 2 Cl 2 , CHCl 3 , CFCl 3 , CCl 2 F 2 , C 2 Cl 2 F 4 , C 2 Cl 3 F 3  and C 2 ClF 5 . Preparation.-The initial unsolvated steroid is first contacted with the halohydrocarbon. Simple suspension with concurrent comminution yields an inventive product. Alternatively the halohydrocarbon is mixed with a solution of the steroid in a conventional steroid solvent (e.g. MeOH, EtOH, Pr<SP>i</SP>OH, HCHO, CH 2 Cl 2 , acetone) and the resulting mixture is either crystallized at low temperature, e.g. -29 to -40 C., or distilled until the conventional solvent has been removed whereupon the solvate crystallizes. The optional removal of the halohydrocarbon from the solvate may be effected by heating at up to 60 C. in a vacuum, and may also take place automatically upon comminution. The latter may be effected ultrasonically or in a ball or fluid energy mill. Anti-inflammatory aerosol compositions comprise a suspension of a product of the invention in an aerosol propellant and a dispersing agent. (The steroid has a modified crystal structure and does not exhibit crystal growth in the propellant.)
Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)\<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
The accurate diagnosis and prognosis of epilepsy represents a significant unmet medical need. Due to the unpredictable nature of seizures, epilepsy is difficult to diagnose and treat. In the United Kingdom (UK), 125,000 people per annum are referred to first seizure clinics with suspected epilepsy of which 40,000 receive a confirmed diagnosis of epilepsy. Although diagnosing a patient with epilepsy is a clinical decision, clinicians often look towards diagnostic tests (such as electroencephalograms - EEGs) to support their decision-making process. At present, in the absence of observable epileptiform abnormalities (abnormal wave forms strongly associated with epilepsy on EEG, there are no clinically robust markers of epilepsy. Mathematical models provide a powerful and useful tool with which to identify and understand biological mechanisms that may lead to the risk of having seizures. By combining mathematical and computational techniques, Neuronostics have developed a biomarker called BioEP. Using properties in the background and clinically non contributary EEG, the investigators have demonstrated in retrospective, multi-site phase I and phase II studies sufficient evidence that could support clinicians to make more informed diagnostic decisions that investigators hope will lead to better and faster decisions about patients' diagnosis and treatment. The investigators will now conduct a prospective single site diagnostic belief updating study to examine the utility of BioEP in supporting clinicians' decision making a clinical setting in the NHS. The investigators will do this by inviting adults to take part who are suspected of having a first seizure and who will attend a first seizure clinic run by a Consultant Nurse for the Epilepsies (CNE) at the Royal Wolverhampton NHS trust. As part of the patients diagnostic work up, patients will have an EEG performed, the investigators will then apply BioEP to the patients EEG to derive a "risk score". This risk score will be presented to the CNE, who may then decide to combine it with the clinical history and clinical test information to help the CNE make decisions about patients' diagnosis and treatment.

The CNE will first rate the probability that the patient has experienced an epileptic seizure and probability of recurrence based on the clinical history and standard EEG (and any other standard tests ordered). A second assessment of this probability will be made after the CNE subsequently receives the BioEP risk score and report to quantify the updating of belief (that the patient has an increased seizure risk) and assess the utility of BioEP as a diagnostic decision support tool.